Science Corp raises $400m to expand its PRIMA vision implant in Europe

Science Corporation, a US brain-computer interface company, has raised $400m in a Series D round, it said in a blog post on Tuesday. The company has now raised more than $900m since it was founded in 2021.

Investors include Khosla Ventures, Tenet Healthcare, Y Combinator, 885 Capital, PLC Neurotech and the Ackman Oxman Institute, among others. Science did not name a lead investor or disclose its valuation.

The round comes eight months after Science raised a $230m Series C, which TechCrunch reportedvalued the company at $1.5bn.

Science is led by Max Hodak, a co-founder and former president of Neuralink. Its main product is PRIMA, a tiny chip implanted under the retina that works with a pair of camera glasses. It is designed for people who have lost central vision to geographic atrophy, a late stage of dry age-related macular degeneration.

PRIMA won a CE mark in July, allowing sales in 30 European countries. The company says it is the first brain-computer interface with a CE mark to restore form vision, meaning the ability to read letters, numbers and words.

Science said it will use the new money to make PRIMA available across more of Europe. It will also prepare for a US launch, seeking FDA approval through the Humanitarian Device Exemption route, a pathway for devices that treat small patient groups.

In addition, the funds will go towards research, manufacturing and the company’s biohybrid brain interface. That project uses lab-grown neurons to link electronics with the brain.

Original source Science Corp raises $400m to expand its PRIMA vision implant in Europe

Back to home